Kineta jumps on positive early-stage tumor treatment trial

Kineta

08/04/2024 21:54

** Therapy developer Kineta's  KA.O  shares rise ~48.3% to
80 cents after market
    ** Company says its therapy KVA12123 in combination with
drugmaker Merck's  MRK.N  Keytruda showed partial response - at
least 30% decrease in cancer - in one patient with a type of
tumor of salivary glands
    ** Combination therapy is being tested on nine patients who
have enrolled for trial    
    ** KA says therapy showed favorable safety and tolerability
during trial on patients
    ** Up to last close, stock down 83.4% in past 12 months   

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))